Article info
PDFCorrespondence response
Response to: ‘Effectiveness and safety of ruxolitinib for the treatment of refractory systemic idiopathic juvenile arthritis like associated with interstitial lung disease: case report’ by Bader-Meunier et al
- Correspondence to Dr Elizabeth D Mellins, Department of Pediatrics, Program in Immunology, Stanford University, Stanford, CA 94305, USA; mellins{at}stanford.edu
Citation
Response to: ‘Effectiveness and safety of ruxolitinib for the treatment of refractory systemic idiopathic juvenile arthritis like associated with interstitial lung disease: case report’ by Bader-Meunier et al
Publication history
- Received February 2, 2020
- Accepted February 3, 2020
- First published February 13, 2020.
Online issue publication
January 12, 2022
Article Versions
- Previous version (13 February 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.